AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1839379 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg of TAP-144-SR
Number of subjects: 36
Study 1839379 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 micrograms/kg of TAP-144-SR
Number of subjects: 36
Study 1839379 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (all doses)
Number of subjects: 36
Study 1839379 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (90 micrograms/kg)
Number of subjects: 36
Study 1839379 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (doses >30 micrograms/kg)
Number of subjects: 36
Study 6406436 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 6406436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31025311 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE framework
Number of subjects: 0
Study 30073471 — intervention group
Group type: EXPERIMENTAL
Intervention: ON-OPIOID
Number of subjects: 200
Study 30073471 — intervention group
Group type: COMPARATOR
Intervention: OPIOID-NAÏVE
Number of subjects: 200
Study 27415850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) consisting of 8 telephone sessions, a patient education book, and a stress management procedure on compact disc.
Number of subjects: 193
Study 27415850 — intervention group
Group type: COMPARATOR
Intervention: Usual Cardiac Care (UCC)
Number of subjects: 193
Study 27415850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 193
Study 24561163 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic impedance sensor with advanced algorithm (SAM algorithm)
Number of subjects: 40
Study 24561163 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 40
Study 21729464 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 49
Study 21729464 — intervention group
Group type: COMPARATOR
Intervention: No breakfast consumption
Number of subjects: 49
Study 19711093 — intervention group
Group type: COMPARATOR
Intervention: Prosaccade training at rest neck position (rest training group)
Number of subjects: 30
Study 19711093 — intervention group
Group type: COMPARATOR
Intervention: Prosaccade training at 20 degrees neck flexion position (neck training group)
Number of subjects: 30
Study 19711093 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained subjects)
Number of subjects: 30
Study 17183021 — intervention group
Group type: EXPERIMENTAL
Intervention: R allele of PON1 Q192R
Number of subjects: 3266
Study 14527931 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus injection of 50 microm/m2 of G‐CSF (SI)
Number of subjects: 6
Study 14527931 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous injection of 50 microm/m2 of G‐CSF for 24 h (CI)
Number of subjects: 6
Study 11428246 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical guidance
Number of subjects: 2
Study 11428246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremoval of the spoon
Number of subjects: 2
Study 9549021 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 21
Study 9549021 — intervention group
Group type: COMPARATOR
Intervention: Control group (EMG machine turned off)
Number of subjects: 21
Study 7509383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediastinal radiotherapy (RT)
Number of subjects: 145
Study 7509383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediastinal radiotherapy plus bleomycin
Number of subjects: 145
Study 7509383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 145
Study 2921725 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue Healon
Number of subjects: 50
Study 2921725 — intervention group
Group type: COMPARATOR
Intervention: Clear sodium hyaluronate (Healon)
Number of subjects: 50
Study 30610516 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia
Number of subjects: 15
Study 30610516 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based anesthesia
Number of subjects: 15
Study 28602580 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapopliteal vein bypass (VB)
Number of subjects: 104
Study 28602580 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty (PBA)
Number of subjects: 104
Study 25521264 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Assessment Battery for Children‐2 (MABC‐2)
Number of subjects: 21
Study 25521264 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion Analysis Laboratory (MAL) data
Number of subjects: 21
Study 25521264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MABC‐2 and MAL data
Number of subjects: 21
Study 23295073 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimode Comprehensive Tailored Information Package (MCTIP)
Number of subjects: 103
Study 23295073 — intervention group
Group type: COMPARATOR
Intervention: Normal information provision
Number of subjects: 103
Study 21777897 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.9 g/d tranexamic acid
Number of subjects: 304
Study 21777897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.95 g/d tranexamic acid
Number of subjects: 304
Study 21777897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 19459424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingavirin (90 mg once daily for 5 days)
Number of subjects: 105
Study 19459424 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbidol (200 mg 4 times a day for 5 days)
Number of subjects: 105
Study 19459424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 17083396 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic orchiopexy
Number of subjects: 82
Study 17083396 — intervention group
Group type: COMPARATOR
Intervention: Open orchiopexy
Number of subjects: 82
Study 17083396 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic second stage Fowler‐Stephens orchiopexy
Number of subjects: 82
Study 17083396 — intervention group
Group type: COMPARATOR
Intervention: Open second stage Fowler‐Stephens orchiopexy
Number of subjects: 82
Study 14713135 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d) plus contingency management
Number of subjects: 151
Study 14713135 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (150 mg/d) plus noncontingent voucher control
Number of subjects: 151
Study 14713135 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus contingency management
Number of subjects: 151
Study 14713135 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus noncontingent voucher control
Number of subjects: 151
Study 10890475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration with half‐Hammersmith dosing regimen of aprotinin
Number of subjects: 0
Study 10890475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration with full‐Hammersmith dosing regimen of aprotinin
Number of subjects: 0
Study 10890475 — intervention group
Group type: COMPARATOR
Intervention: No hemofiltration with half‐Hammersmith dosing regimen of aprotinin
Number of subjects: 0
Study 10890475 — intervention group
Group type: COMPARATOR
Intervention: No hemofiltration with full‐Hammersmith dosing regimen of aprotinin
Number of subjects: 0
Study 10890475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 0
Study 10890475 — intervention group
Group type: COMPARATOR
Intervention: No hemofiltration
Number of subjects: 0
Study 8851621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1,000 mg intravenously 30 min before anesthesia (group 1)
Number of subjects: 20
Study 8851621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1,000 mg intravenously followed by a second 1,000 mg at initiation of cardiopulmonary bypass (group 2)
Number of subjects: 20
Study 1620414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 20
Study 1620414 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 20
Study 6422868 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain enriched therapy at 0.7 gm/kg/day of branched chain amino acids
Number of subjects: 23
Study 6422868 — intervention group
Group type: COMPARATOR
Intervention: Balanced parenteral nutrition with 1.5 gm/kg/day of amino acids, 30 calories/kg/day of glucose, and 7 calories/kg/day of fat
Number of subjects: 23
Study 30944164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (continuing)
Number of subjects: 293
Study 30944164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (in vitro)
Number of subjects: 293
Study 30944164 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (stopping)
Number of subjects: 293
Study 30708068 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive health knowledge score based on a questionnaire with 28 items
Number of subjects: 412
Study 30708068 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of participants
Number of subjects: 412
Study 30708068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' education level
Number of subjects: 412
Study 30708068 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of violence
Number of subjects: 412
Study 28818422 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group (EX)
Number of subjects: 42
Study 28818422 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 42
Study 25986030 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical staging and RCTX (arm A)
Number of subjects: 255
Study 25986030 — intervention group
Group type: COMPARATOR
Intervention: RCTX (arm B)
Number of subjects: 255
Study 24170747 — intervention group
Group type: COMPARATOR
Intervention: Patient self-management (OL)
Number of subjects: 48
Study 24170747 — intervention group
Group type: EXPERIMENTAL
Intervention: International artificial pancreas (iAP)
Number of subjects: 48
Study 24170747 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Cambridge (CAM)
Number of subjects: 48
Study 21358538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometric device (IG)
Number of subjects: 1832
Study 20127537 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg i.v. Lornoxicam
Number of subjects: 2
Study 20127537 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 2
Study 17174387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=217)
Number of subjects: 555
Study 17174387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=168)
Number of subjects: 555
Study 15481277 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy progressive resistance training (RE) twice a week for 12 weeks
Number of subjects: 18
Study 15481277 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises (CON)
Number of subjects: 18
Study 11966504 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 28
Study 11966504 — intervention group
Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 28
Study 9541173 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 14
Study 9541173 — intervention group
Group type: COMPARATOR
Intervention: Bedtime NPH insulin
Number of subjects: 14
Study 8291156 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 200
Study 8291156 — intervention group
Group type: COMPARATOR
Intervention: Total meniscectomy
Number of subjects: 200
Study 2656442 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g piracetam/day i.v. followed by 3 x 800 mg/day p.o. for 8 weeks
Number of subjects: 40
Study 2656442 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v. and then p.o.
Number of subjects: 40
Study 29548719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR FCDP (10/1000 mg)
Number of subjects: 40
Study 29548719 — intervention group
Group type: COMPARATOR
Intervention: Individual component tablets (dapagliflozin [10 mg] plus metformin XR [2 × 500 mg])
Number of subjects: 40
Study 28895887 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose (HD: high dose)
Number of subjects: 246
Study 28895887 — intervention group
Group type: EXPERIMENTAL
Intervention: 5X/week (MD: Moderate Dose)
Number of subjects: 246
Study 28895887 — intervention group
Group type: EXPERIMENTAL
Intervention: 3X/week (LD: Low Dose)
Number of subjects: 246
Study 28895887 — intervention group
Group type: COMPARATOR
Intervention: Unfortified (Control)
Number of subjects: 246
Study 25530347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment
Number of subjects: 62
Study 25530347 — intervention group
Group type: COMPARATOR
Intervention: Control group (sensory stimulation without RF lesioning)
Number of subjects: 62
Study 23479321 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/tuberculosis subjects with high CD4 T-cell count (≥ 350/μL)
Number of subjects: 0
Study 23479321 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/tuberculosis subjects with low CD4 T-cell count (<350/μL)
Number of subjects: 0
Study 23479321 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/tuberculosis patients with CD4 T-cell count ≥ 350/μL
Number of subjects: 0
Study 20921029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity therapy (Group A): 3 two-month blocks, 4 sessions per week (30-45 minutes each), total 96 sessions
Number of subjects: 50
Study 20921029 — intervention group
Group type: COMPARATOR
Intervention: Continuous low-intensity therapy (Group B): 2 sessions per week (30-45 minutes each), total 104 sessions
Number of subjects: 50
Study 20921029 — intervention group
Group type: COMPARATOR
Intervention: Group B (Continuous low-intensity therapy)
Number of subjects: 50
Study 19589952 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated muscle temperature during cycling at 75% ventilatory threshold
Number of subjects: 16
Study 19589952 — intervention group
Group type: COMPARATOR
Intervention: Control (normal muscle temperature) during cycling at 75% ventilatory threshold
Number of subjects: 16
Study 16396977 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg/day)
Number of subjects: 1346
Study 16396977 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (0 to 3 years)
Number of subjects: 1346
Study 16396977 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 1346
Study 15335093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate gel
Number of subjects: 48
Study 15335093 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem extract gel
Number of subjects: 48
Study 15335093 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 48
Study 11071803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lisinopril (32.5-35 mg/day)
Number of subjects: 3164
Study 11071803 — intervention group
Group type: COMPARATOR
Intervention: Low-dose lisinopril (2.5-5 mg/day)
Number of subjects: 3164
Study 9186877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (N = 42)
Number of subjects: 83
Study 9186877 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (N = 41)
Number of subjects: 83
Study 9186877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine or Terbutaline (N = 14)
Number of subjects: 83
Study 9186877 — intervention group
Group type: COMPARATOR
Intervention: Saline and Morphine (N = 12)
Number of subjects: 83
Study 8084977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 100
Study 8084977 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 100
Study 8084977 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 100
Study 8084977 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 100
Study 8084977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (maintenance therapy)
Number of subjects: 100
Study 8084977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic approaches (ECT, sleep deprivation, light therapy)
Number of subjects: 100
Study 7142413 — intervention group
Group type: EXPERIMENTAL
Intervention: CS plus rational self‐statements
Number of subjects: 0
Study 7142413 — intervention group
Group type: COMPARATOR
Intervention: CS plus irrational self‐statements
Number of subjects: 0
Study 7142413 — intervention group
Group type: COMPARATOR
Intervention: CS alone
Number of subjects: 0
Study 30910420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and cognitive training (EX/CT) program
Number of subjects: 69
Study 30910420 — intervention group
Group type: COMPARATOR
Intervention: Usual care attention control (UCAC) stretching and flexibility program
Number of subjects: 69
Study 28150513 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RA
Number of subjects: 208
Study 28150513 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 208
Study 24968129 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20-2 ppm for 24 days
Number of subjects: 125
Study 24968129 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 2 ppm
Number of subjects: 125
Study 24968129 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iNO)
Number of subjects: 125
Study 24968129 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 125
Study 23705849 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care with duloxetine
Number of subjects: 189
Study 23705849 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care with placebo
Number of subjects: 189
Study 23705849 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine alone
Number of subjects: 189
Study 21714365 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-oriented discharge planning intervention (manualised, two sessions at discharge and 3 months thereafter)
Number of subjects: 491
Study 19144162 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help online
Number of subjects: 0
Study 19144162 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy online
Number of subjects: 0
Study 19144162 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 0
Study 17699475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX)
Number of subjects: 1157
Study 17699475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study 16520559 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12 weeks, 60 minutes per session, 5 times per week)
Number of subjects: 44
Study 16520559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 12930486 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-blocker (placebo purported to block anxiety)
Number of subjects: 0
Study 12930486 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-enhancer (placebo purported to enhance memory)
Number of subjects: 0
Study 10323447 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD + prednisolone
Number of subjects: 26
Study 10323447 — intervention group
Group type: COMPARATOR
Intervention: DMARD alone
Number of subjects: 26
Study 10323447 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 26
Study 8984133 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once a day
Number of subjects: 407
Study 8984133 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg once a day
Number of subjects: 407
Study 1665179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg and Hydrochlorothiazide 12.5 mg once daily (L/HCTZ)
Number of subjects: 165
Study 1665179 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg and Hydrochlorothiazide 25 mg once daily (C/HCTZ)
Number of subjects: 165
Study 7099904 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min. of steady-state treadmill running
Number of subjects: 18
Study 7099904 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min. of treadmill running followed by progressively increasing speed until exhaustion
Number of subjects: 18
Study 7099904 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 29915931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberosity grafts (TG)
Number of subjects: 20
Study 29915931 — intervention group
Group type: COMPARATOR
Intervention: Lateral palate grafts (PG)
Number of subjects: 20
Study 28689046 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCAS mechanical chest compression
Number of subjects: 1035
Study 28689046 — intervention group
Group type: COMPARATOR
Intervention: Manual chest compression
Number of subjects: 1035
Study 26106632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam‐ketamine
Number of subjects: 38
Study 26106632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam‐fentanyl
Number of subjects: 38
Study 23060628 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 113
Study 23060628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 22340165 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery hook
Number of subjects: 120
Study 22340165 — intervention group
Group type: COMPARATOR
Intervention: Titanium clip
Number of subjects: 120
Study 19144212 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term use of rivastigmine
Number of subjects: 29
Study 16239239 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital in the Home (early discharge)
Number of subjects: 104
Study 12972723 — intervention group
Group type: EXPERIMENTAL
Intervention: semi-standardized acupuncture (150 patients)
Number of subjects: 300
Study 12972723 — intervention group
Group type: EXPERIMENTAL
Intervention: minimal acupuncture at non-acupuncture points (75 patients)
Number of subjects: 300
Study 12972723 — intervention group
Group type: COMPARATOR
Intervention: no treatment for two months followed by semi-standardized acupuncture (75 patients, waiting list control)
Number of subjects: 300
Study 10755576 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.05 mg/kg subcutaneously)
Number of subjects: 15
Study 10755576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8757210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-allergen gloves
Number of subjects: 52